KDR and cancer: Accordingly, anticancer drugs that inhibit VEGFR-2 such as sorafenib [26], regorafenib [27], pazopanib [28], sunitinib [29], tivozanib [30], and lenvatinib [31], are selective and effective against many cancer types [32,33,34,35,36], (Figure 1).